United Therapeutics CorporationUTHR
Close of Friday, October 23, 2026 · United Therapeutics Corporation is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$587.46
vs its Pivot
+11.1%
OnlyAlpha Score
73
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +24.4% | +20.6% | +39.3% | +36.6% | +25.7% |
No dividend in the last 12 months.
Who runs and owns it
Run by Martine Rothblatt (founder, chair & CEO), one of the Forbes billionaires.
In these funds
IBB · 1.70%IYH · 0.38%IYY · 0.03%IJH · 0.00%
Big investors that own it (latest 13F)
| Renaissance Technologies | 1.3% of holdings |
| Texas A&M / UT | 0.6% of holdings |
| Bridgewater Associates | 0.2% of holdings |
Suppliers, customers and partners
Sells to UTHR
| MannKind | Tyvaso DPI manufacturing/supply |
| DEKA Research & Development (private) | sole manufacturer of Remunity pumps |
UTHR sells to
| Cigna Group (Express Scripts/Evernorth) | Accredo; Tyvaso via spec. distributors 59% of rev |
| CVS Health | CVS Specialty; Tyvaso via spec. distributors 59% of rev |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get UTHR in your free daily emailAfter every close: whether UTHR is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track UTHR free → Full Stock check
Track UTHR free → Full Stock check